Hipertensión arterial secundaria

1. Mancia G, Fagard R, Narkiewicz K, et al.
2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34: 2159–2219.
2. Streeten DH, Anderson GH Jr,Wagner S. Effect of age on response of secondary hypertension to specific treatment. Am J Hypertens 1990;3:360–365.
3. Muiesan ML, Rizzoni D, Salvetti M, Porteri E, Monteduro C, Guelfi D, Castellano M, Garavelli G, Agabiti-Rosei E. Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens 2002;20:1439–1444.
4. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens
1994;12:609–615.
5. Borgel J, Springer S, Ghafoor J, Arndt D, Duchna HW, Barthel A, Werner S, Van Helden J, Hanefeld C, Neubauer H, Bulut D, Mugge A. Unrecognized secondary causes of hypertension in patients with hypertensive urgency/emergency:  prevalence and co-prevalence. Clin Res Cardiol 2010;99:499–506.
6. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004;27:193–202.
7. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987;147:1289–1293.
8. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, WhiteW, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Esistan hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:510–526.
9. ArarMY, Hogg RJ, Arant BS Jr, Seikaly MG. Etiology of sustained hypertension in children in the southwestern United States. Pediatr Nephrol 1994;8:186–189.
10. Pedrosa RP, Drager LF,Gonzaga CC, SousaMG,de Paula K,AmaroAC,AmodeoC, Bortolotto LA, Krieger EM, Bradley TD, Lorenzi-Filho G. Obstructive sleep apnea: the mostcommon secondary cause of hypertension associated with resistant hypertension. Hypertension 2011;58:811–817.
11. DaviesCW, Crosby JH, Mullins RL, Barbour C, Davies RJ, Stradling JR. Case-control study of 24 hour ambulatory blood pressure in patients with obstructive sleep apnoea and normal matched control subjects. Thorax 2000;55:736–740.
12. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006;354:2368–2374.
13. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation 2005;112:1362–1374.
14. Leertouwer TC, Pattynama PM, van den Berg-Huysmans A. Incidental renal artery stenosis in peripheral vascular disease: a case for treatment? Kidney Int 2001;59: 1480–1483.
15. Messerli FH, Ventura HO, Amodeo C. Osler’s maneuver and pseudohypertension. N Engl J Med 1985;312:1548–1551.
16. Belmin J, Visintin JM, Salvatore R, Sebban C, Moulias R. Osler’s maneuver: absence of usefulness for the detection of pseudohypertension in an elderly population. Am J Med 1995;98:42–49.
17. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005;111:697–716.
18. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G,  ricelli C, Brignoli O, Caputi AP. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005;23:2093–2100.
19. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Zampi I, Gattobigio R, Sacchi N, Porcellati C. White coat hypertension and white coat effect. Similarities and differences. Am J Hypertens 1995;8:790–798.
20. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012;125:14–22.
21. Izhar M, Alausa T, Folker A, Hung E, Bakris GL. Effects of COX inhibition on blood pressure and kidney function inACEinhibitor-treated blacks and hispanics. Hypertension 2004;43:573–577.
22. Sudano I, Flammer AJ, Periat D, Enseleit F, Hermann M,Wolfrum M, Hirt A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Holzmeister J, Nussberger J, Mocharla P, Landmesser U, Haile SR, Corti R, Vanhoutte PM, Luscher TF, Noll G, Ruschitzka F. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010;122:1789–1796.
23. Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S. Liquorice-induced rise in blood pressure: a linear dose-response  relationship. J Hum Hypertens 2001;15:549–552.
24. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, Colditz GA, Stampfer MJ. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996;94:483–489.
25. Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, Hanson P, Mohanty PK, Victor RG. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990;323:693–699.
26. Kappers MH, van Esch JH, SluiterW, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010;56:675–681.
27. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19:927–934.
28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
29. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779–1802.
30. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48:9–17.
31. Kikuya M, Hansen TW, Thijs L, Bjorklund-Bodegard K, et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 2007;115:2145–2152.
32. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013;31:1731–1768.
33. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, Reboldi G. Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. Hypertension 2007;49:777–783.
34. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma. Circulation 1997;95:1471–1478.
35. Cloward TV, Walker JM, Farney RJ, Anderson JL. Left ventricular hypertrophy is a common echocardiographic abnormality in severe obstructive sleep apnea and reverses with nasal continuous positive airway pressure. Chest 2003;124:594–601.
36. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001;19:2271–2277.
37. Iber C, Ancoli-Israel S, Chesson A, Quan S. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. 1st edn.Westchester, IL, 2007.
38. Alonso-Fernandez A, Garcia-Rio F, Racionero MA, Pino JM, Ortuno F, Martinez I, Villamor J. Cardiac rhythm disturbances and ST-segment depression episodes in patients with obstructive sleep apnea-hypopnea syndrome and its mechanisms. Chest 2005;127:15–22.
39. Fletcher EC. Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep 2003;26:15–19.
40. Leuenberger UA, Brubaker D, Quraishi S, Hogeman CS, Imadojemu VA, Gray KS. Effects of intermittent hypoxia on sympathetic activity and blood pressure in humans. Auton Neurosci 2005;121:87–93.
41. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004;125:112–117.
42. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004;43:518–524.
43. Ip MS, Tse HF, Lam B, TsangKW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med 2004;169:348–353.
44. Rimoldi SF, Rexhaj E, Pratali L, Bailey DM, Hutter D, Faita F, Salmon CS, Villena M, Nicod P, Allemann Y, Scherrer U, Sartori C. Systemic vascular dysfunction in patients with chronic mountain sickness. Chest 2012;141:139–146.
45. Bruno RM, Rossi L, Fabbrini M, Duranti E, et al. Renal vasodilating capacity and endothelial function are impaired in patients with obstructive sleep apnea syndrome and no traditional cardiovascular risk factors. J Hypertens 2013;31:1456–1464.
46. Bailey DM, Rimoldi SF, Rexhaj E, Pratali L, et al. Oxidative-nitrosative stress and systemic vascular function in highlanders with and without exaggerated hypoxemia. Chest 2013;143:444–451.
47. Jurado-Gamez B, Fernandez-Marin MC, Gomez-Chaparro JL, Munoz-Cabrera L, Lopez-Barea J, Perez-Jimenez F, Lopez-Miranda J. Relationship of oxidative stress and endothelial dysfunction in sleep apnoea. Eur Respir J 2011;37:873–879.
48. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJ. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomized parallel trial. Lancet 2002;359:204–210.
49. Becker HF, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan CE, Peter JH. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003;107:68–73.
50. Logan AG, Tkacova R, Perlikowski SM, Leung RS, Tisler A, Floras JS, Bradley TD. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur Respir J 2003;21:241–247.
51. Suzuki M, Otsuka K, Guilleminault C. Long-term nasal continuous positive airway pressure administration can normalize hypertension in obstructive sleep apnea patients. Sleep 1993;16:545–549.
52. JohnsMW.Anewmethod for measuring daytime sleepiness: theEpworth sleepiness scale. Sleep 1991;14:540–545.
53. JohnsMW. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 1993;103:30–36.
54. Thurnheer R, Bloch KE, Laube I, Gugger M, Heitz M. Respiratory polygraphy in sleep apnoea diagnosis. Report of the Swiss respiratory polygraphy registry and systematic review of the literature. Swiss Med Wkly 2007;137:97–102.
55. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, et al. Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008;51:S13–S20.
56. Slovut DP, Olin JW. Fibromuscular dysplasia. N Engl J Med 2004;350:1862–1871. 57. Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC, Ishani A, Collins AJ, Foley RN. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int 2005;68: 293–301.
58. Rimoldi SF, de Marchi SF, Windecker S, Meier B, Allemann Y. Screening renal artery angiography in hypertensive patients undergoing coronary angiography and 6-month follow-up after ad hoc percutaneous revascularization. J Hypertens 2010; 28:842–847.
59. Textor SC, Lerman L. Renovascular hypertension and ischemic nephropathy. Am J Hypertens 2010;23:1159–1169.
60. Messerli FH, Bangalore S, Makani H, Rimoldi SF, Allemann Y, White CJ, Textor S, Sleight P. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. Eur Heart J 2011;32:2231–2235. Secondary arterial hypertension
61. Rimoldi SF, Yuzefpolskaya M, Allemann Y, Messerli F. Flash pulmonary edema. Prog Cardiovasc Dis 2009;52:249–259.
62. Baumgartner I, Lerman LO. Renovascular hypertension: screening and modern management. Eur Heart J 2011;32:1590–1598.
63. Mangiacapra F, Trana C, Sarno G, Davidavicius G, Protasiewicz M, Muller O, Ntalianis A, Misonis N, Van Vlem B, Heyndrickx GR, De Bruyne B. Translesional pressure gradients to predict blood pressure response after renal artery stenting in patients with renovascular hypertension. Circ Cardiovasc Interv 2010;3:537–542.
64. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344:431–442.
65. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D’Agostino RB, Dworkin LD. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2013;doi: 10.1056/NEJMoa1310753.
66. de Leeuw PW, Postma CT, Kroon AA. Treatment of atherosclerotic renal artery stenosis: time for a new approach. JAMA 2013;309:663–664.
67. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G,Ruilope L, van de Borne P, Tsioufis C. ESH position paper: renal denervation—an interventional therapy of resistant hypertension. J Hypertens 2012;30:837–841.
68. RossiGP, Bernini G, CaliumiC, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J AmColl Cardiol 2006;48:2293–2300.
69. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, YoungWFJr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004;89:1045–1050.
70. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266–3281.
71. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosteroneproducing adenoma. J Hypertens 2007;25:1433–1442.
72. Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, Mosso L, Marafetti L, Veglio F, Maccario M. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2006;91:2618–2623.
73. Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, DeinumJ. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009;151:329–337.
74. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet 2006;367:1605–1617.
75. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526–1540.
76. Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004;89:1222–1226.
77. Young WF Jr. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. Rev Endocr Metab Disord 2007;8:309–320.
78. Prisant LM, Mawulawde K, Kapoor D, Joe C. Coarctation of the aorta: a secondary cause of hypertension. J Clin Hypertens (Greenwich) 2004;6:347–350.
79. Weber HS, Cyran SE. Endovascular stenting for native coarctation of the aorta is an effective alternative to surgical intervention in older children. Congenit Heart Dis 2008;3:54–59.
80. Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease. Eur Heart J 2010;31:2915–2957.
81. Messerli FH, Nachbur B, Senn A, Tuckman J. Hypertension in coarctation of the abdominal aorta. Schweiz Med Wochenschr 1973;103:307–308.
82. Stewart AB, Ahmed R, Travill CM, Newman CG. Coarctation of the aorta life and health 20–44 years after surgical repair. Br Heart J 1993;69:65–70.
83. Brown ML, Burkhart HM, Connolly HM, Dearani JA, Cetta F, Li Z, Oliver WC, Warnes CA, Schaff HV. Coarctation of the aorta: lifelong surveillance is mandatory following surgical repair. J Am Coll Cardiol 2013;62:1020–1025.